Todd L. Cecil - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Todd L. Cecil


Todd L. Cecil
Vice-President,
Compendial Science,
United States Pharmacopeia

Todd L. Cecil, PhD, is the vice-president of compendial science at USP. He has been with the organization since 1993 and has held the following positions: director of noncomplex actives and general policies and requirements; project manager of new monograph development project; scientist; and chemist III.

Cecil is presently a member of the American Association of Pharmaceutical Scientists (AAPS) and ACS. While at AAPS, he has held the positions of secretary treasurer, vice-chair, chair-elect, chair, and past-chair of the APQ Section of AAPS; chair APQ Workshop Committee; and AAPS APQ lead paper screener. He is the author of seven publications and has made more than 60 national and international presentations.

He holds a BS in chemistry from the University of Iowa and a PhD in analytical chemistry from Virginia Commonwealth University.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
40%
The US economic recovery
14%
Improved credit and financing flow to the small to emerging pharma/bio sector
14%
Less restrictive inventory control by pharmaceutical companies
9%
The level of competition from contract manufacturers in emerging markets
24%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
Federal Spending Freeze Could Threaten Supply-Chain Security
FindPharma Custom Search

Click here